How long does immunotherapy take to work for triple-negative breast cancer?

Triple-negative breast cancer lacks three receptors commonly used to guide treatment, so treatment planning depends on the cancer’s stage, tumour features and previous or planned therapies. Immunotherapy helps the immune system recognise and attack cancer cells, but the visible change on a scan may lag behind changes in immune activity.

Some people notice symptom changes before imaging gives a clear answer; others have no early symptom change even when treatment is having an effect. A scan may show shrinkage, stability or a change that needs repeat assessment. Your oncologist combines these findings with blood tests and treatment tolerance rather than judging treatment from a single day.

Attend scheduled infusions, examinations and imaging appointments, and keep a simple record of new symptoms, their onset and whether they are changing. Do not stop treatment or start supplements without discussing them with your oncology team.

Tell the team about medicines, autoimmune conditions, breathing problems, bowel changes, skin changes or unusual tiredness. These details help distinguish cancer-related symptoms from immune-related treatment effects and guide decisions about continuing, pausing or changing therapy.

Contact your cancer team promptly for new or worsening breathlessness, chest pain, severe diarrhoea, marked abdominal pain, yellowing of the skin or eyes, a widespread rash, confusion, severe weakness or a high temperature. Rapid assessment matters because immune-related inflammation can affect organs and may need treatment.

Ask which scan or examination will be used to assess your response, when it is planned, and what result would lead to continuing the current treatment. Ask how your symptoms should be reported after an infusion and which medicines or supplements should be avoided.